Founded Year

2015

Stage

Series B - II | Alive

Total Raised

$16.7M

Last Raised

$1.68M | 2 yrs ago

About DeepBio

DeepBio is a developer of prostate cancer diagnosis software. The company's product features a convolutional neural network that detects and grades prostate cancer from needle biopsy images.

DeepBio Headquarters Location

#610~613, 27 Digital-ro 33-gil Guro-gu

Seoul, 08394,

South Korea

+82 70 7703 4746

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

DeepBio's Products & Differentiation

See DeepBio's products and how their products differentiate from alternatives and competitors

  • DeepDx® Prostate

    Clinically validated AI Software for Prostate Cancer. The software detects cancer and grades its severity on whole slide images (WSIs) of H&E-stained prostate core needle biopsy samples, based on the Gleason scoring system (most common assessment of prostate cancer severity and prognosis). It generates colored overlays of Gleason patterns 3, 4, and 5. The areas of each Gleason pattern out of the total tumor area are automatically quantified as well as the tumor-to-tissue ratio. Automatic measurements of the total tissue and the total tumor lengths are also provided. It takes only 30 seconds per core to get AI analysis. In a clinical validation, its performance was demonstrated to provide specialist-level support. The sensitivity and specificity of the software on detecting cancer were 99% and 94% respectively.

Research containing DeepBio

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned DeepBio in 1 CB Insights research brief, most recently on Jun 11, 2020.

Expert Collections containing DeepBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DeepBio is included in 6 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

8,452 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

8,260 items

Latest DeepBio News

Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Korean Public Procurement Service

Jul 26, 2022

This designation marks the Korean government’s recognition of innovation for DeepDx-Prostate Pro Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that its AI solution for grading the severity of prostate cancer, DeepDx-Prostate Pro, has been officially designated as an ‘Innovative Product (Fast Track II)’ by the Korean Public Procurement Service (PPS) in the bio-health sector, a public recognition of product excellence and innovation. ‘Innovative Product Designation Program’ is a government program that aims to foster the development of innovative technologies and is operated by the Korean PPS, providing public access to breakthrough technologies. To select Innovative Products, a committee made up of the Korea PPS and experts in each field, such as bio-health, future automobiles, carbon neutrality, evaluate each registrant based on several criteria including public value and innovation. As a result, Deep Bio can now execute a purchase agreement with the PPS, and the product can be registered in the Public Procurement Market. With the registration of DeepDx-Prostate Pro in the Public Procurement Market through this designation, the software as a medical device is now available to more than 300K national- and public institutions for purchase. With this opportunity, Deep Bio is expected to lay the groundwork for market expansion as well as demonstrate the clinical utility of its software. Related Posts “We are delighted that the Korean PPS designated DeepDx-Prostate Pro as an Innovative Product. It represents an official government recognition of the innovation of our state-of-the-art technology. Through this, potential clients at national- and public institutions can better access Deep Bio’s groundbreaking software for purchase”, said Sun-Woo Kim, CEO of Deep Bio. “We also hope that this will be a great opportunity to confirm the robust performance and value of our software when implemented into real clinical workflows,” added he. DeepDx-Prostate Pro is a deep learning-based medical software that assists the histopathological diagnosis of prostate cancer by analyzing the Whole Slide Image (WSI) of the prostate needle biopsies. It automatically classifies the severity of prostate cancer based on the Gleason grading system, which is the most widely-used method for evaluating the degree of differentiation of prostate cancer tissues. The software has received Korea MFDS (Ministry of Food and Drug Safety) approval as a Class III medical device in November 2021. In a clinical validation study, the analysis by the software showed high concordance with the reference standard established by experienced board-certified pathologists. In addition, the software improved workflows by significantly reducing time spent by pathologists on analysis of each slide. The study results were published in Modern Pathology. Focusing not only on AI diagnostics but also on R&D, Deep Bio has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, as well as in various international conferences and events. The company also continues to build its global presence through overseas digital pathology solution providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US.

DeepBio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DeepBio Rank

  • When was DeepBio founded?

    DeepBio was founded in 2015.

  • Where is DeepBio's headquarters?

    DeepBio's headquarters is located at #610~613, 27 Digital-ro 33-gil Guro-gu, Seoul.

  • What is DeepBio's latest funding round?

    DeepBio's latest funding round is Series B - II.

  • How much did DeepBio raise?

    DeepBio raised a total of $16.7M.

  • Who are the investors of DeepBio?

    Investors of DeepBio include NH Investment & Securities, Hyundai Venture Investment Corporation, Shinhan Venture Investment, Dt&Investment, Maple Investment Partners and 9 more.

  • Who are DeepBio's competitors?

    Competitors of DeepBio include Lunit and 3 more.

  • What products does DeepBio offer?

    DeepBio's products include DeepDx® Prostate.

  • Who are DeepBio's customers?

    Customers of DeepBio include Lumea.

You May Also Like

Iterative Scopes Logo
Iterative Scopes

Iterative Scopes is a software-only gastrointestinal data company that is working to deliver AI toolkits to the practice of gastroenterology.

Koios Medical Logo
Koios Medical

Koios Medical is a provider of software solutions for radiologists diagnosing cancer. Using AI algorithms trained on thousands of images combined with data from pathology results, Koios DS™ is decision support for healthcare diagnostics. Koios Medical was formerly known as Clearview Diagnostics. The company was founded in 2012 and is based in Chicago, Illinois.

QUIBIM Logo
QUIBIM

Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.

ScreenPoint Medical Logo
ScreenPoint Medical

ScreenPoint Medical, based in Nijmegen, has developed smart software for improving results of breast cancer screening. This software reads mammograms like a human reader and supports radiologists by identifying and interpreting potential problem areas on x-ray images. This reduces the chance of missing tumors and may be used to organize screening more efficiently.

PathAI Logo
PathAI

PathAI provides AI-powered research tools and services for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.

Densitas Logo
Densitas

Densitas supports value-based care through advanced healthcare analytics powered by A.I. at the patient, clinic, and system levels. Its solutions provide on-demand insights for tailored risk-based management of patients and enable healthcare administrators to monitor clinical, quality, and operational performance indicators. The platform is uniquely designed to be fully PACS-centric by operating on the routinely archived standard DICOM images that radiologists review and supports point-of-care and retrospective processing of mammograms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.